Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience. - Wikidata - awgldk - TriplyDB

Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.

Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.

http://www.wikidata.org/entity/Q37138914

about

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration.

P2860

Q42590257-39D4577F-FB18-4226-A4CF-513ED6EE6F69

P2860

Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.

http://www.wikidata.org/entity/Q37138914

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intracoronary abciximab use in ...... a single operator experience.

@en

Intracoronary abciximab use in ...... a single operator experience.

@nl

type

label

Intracoronary abciximab use in ...... a single operator experience.

@en

Intracoronary abciximab use in ...... a single operator experience.

@nl

prefLabel

Intracoronary abciximab use in ...... a single operator experience.

@en

Intracoronary abciximab use in ...... a single operator experience.

@nl

P1433

Q37138914-79E5BF25-6946-4BB2-A9F4-B7EF9E9DA0B5

P1476

Q37138914-F888E3CE-E541-46A0-A530-4FA4172F5D1C

P2093

Q37138914-2596E6A0-C1B9-4BFF-9585-B11E643963B3

Q37138914-A7EC0442-F25D-4D56-906B-28E9762518CE

Q37138914-D79A170A-5266-4DB7-B3B9-53043FA1398B

P2860

Q37138914-2B9AAF94-2E9B-4E98-8783-9276991DD6D5

Q37138914-2BB3D44F-2985-450F-80B9-07FDBF9FC935

Q37138914-48CC0C44-8A94-4994-8FA5-703EDC9E59E1

Q37138914-491073B6-912E-4A32-8102-2EBF93F3626E

Q37138914-4A59FE06-360E-4FCA-9972-56C75CF8D9F9

Q37138914-5131710C-1B47-4F70-9327-C4A2456F7AFA

Q37138914-619F3963-67DB-4797-A72D-28F5DB80289A

Q37138914-782F3FF2-1F8D-4E63-B9D9-A94AA1D7CF06

Q37138914-8DD9144E-86C5-45BF-9756-5866AAEF5F76

Q37138914-9893DE43-ABCF-43CC-AA28-2675F4EAF047

P304

Q37138914-D8389FCD-3F8E-4BA5-9482-4EA6677072D4

P31

Q37138914-737E4B26-09A1-4D56-AA28-9C57366534B3

P356

Q37138914-1DA2563A-6953-491E-929E-41BC86C1551E

P433

Q37138914-6809666C-6770-4ED5-A130-60E3C9370599

P478

Q37138914-293325F9-EDBD-49C0-A4E8-E7B42FFBA1D1

P577

Q37138914-91373ED8-8A5A-4665-ACD9-47B851AD98E1

P698

Q37138914-9CED88C6-92C6-4D13-BC5A-F48EAAC4F7B1

P356

1074248408316485

P1433

Journal of Cardiovascular Pharmacology and Therapeutics

P1476

Intracoronary abciximab use in ...... a single operator experience.

@en

P2093

Daniel A N Mascarenhas

http://www.w3.org/2001/XMLSchema#string

Hiralal Rana

http://www.w3.org/2001/XMLSchema#string

Sandeep S Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis

Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention

Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial

ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Perc

Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting.

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?

Rationale for intracoronary administration of abciximab.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting.

P304

89-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1074248408316485

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18413897

http://www.w3.org/2001/XMLSchema#string